靶向活检足以用于早期前列腺癌主动监测男性
该研究纳入821例接受MRI融合活检的早期前列腺癌主动监测患者,评估靶向活检是否足以识别优势病灶。结果显示靶向检测与系统采样在95%病例中重叠,仅5%病例系统活检独有发现,其中仅2%具有侵袭性风险特征,作者认为靶向活检可能足以用于监测。
要点
- 821例中82%为GG1,18%为GG2;62%首次融合活检为诊断或确认性。
- 靶向检测与系统采样在95%病例中重叠,5%系统活检独有发现。
- 独有病灶中73%为低体积GG2且有利组织学亚型,仅2%有侵袭性风险特征。
核心结论
- MRI融合靶向活检在95%病例中识别优势GG和位置,作者认为不联合系统采样可能足以监测主动监测男性。
研究设计与样本
- 纳入接受主动监测的早期前列腺癌男性(PSA<20,cT1-2,GG1-2),均接受2次以上系统活检,伴或不伴MR靶向采样。
主要发现
- 821例接受MR融合活检男性中82%诊断为GG1,18%为GG2;62%首次融合活检为诊断或确认性。
- 所有融合活检中,靶向检测GG和/或肿瘤位置与系统采样重叠95%;5%病例系统活检独有检测到靶外GG和位置。
- 靶外独有病灶多数为边缘侵袭性特征:73%为低体积GG2且有利组织学亚型。
关键数值与推荐
- 25%的优势病灶与靶区相邻,提示更好的靶区采样可改善检测。
- 5%男性靶区外有更高级别低体积病变,其中仅2%具有侵袭性风险特征。
临床怎么用
- 作者认为MR融合靶向而不联合系统采样可能足以监测主动监测男性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Serial biopsy is a mainstay for patients on active surveillance (AS) for prostate cancer. multiparametric MRI targeting has become a standard. It is unclear whether targeted biopsy alone reliably identifies the dominant lesion, thereby obviating the need for systematic sampling. MATERIALS AND METHODS: Participants enrolled in AS with early-stage prostate cancer (PSA <20, cT1-2, GG1-2) and underwent 2+ systematic biopsy sessions with or without magnetic resonance (MR)-targeted sampling. The findings for dominant Gleason Grade Group (GG) and tumor localization were assessed. RESULTS: Among 821 men who underwent MR fusion biopsies, 82% were diagnosed with GG1 and 18% with GG2. Sixty-two percent had their first MR fusion biopsy as diagnostic or confirmatory. Across all fusion biopsies, MRI-targeted detection of GG and/or tumor location overlapped with systematic sampling for 95% of cases. For 5% of cases, systematic biopsy was unique in detecting GG and location outside the target. Most unique lesions detected outside the target had marginally aggressive features: 73% GG2 of low-volume and favorable histologic subtypes. CONCLUSIONS: In men with MR fusion biopsies, targeting alone identified the dominant GG and location most of the time (95%); 25% of dominant lesions were contiguous to the target, suggesting that better sampling of the target improves detection. The remaining 5% of men had higher-grade, low-volume disease outside the targeted lesion, of which only 2% had aggressive risk features. MR fusion targeting, without systematic sampling, may be sufficient to monitor men on AS. Few high-risk cancers are missed, all of limited volume and favorable histology.
引用
- Fakunle MO, Cowan JE, Washington SL, et al. Targeted Biopsy Is Sufficient for Men on Active Surveillance for Early-Stage Prostate Cancer. J Urol. 2024. PMID: 39383376. doi:10.1097/JU.0000000000004265
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。